Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397384 · ClinicalTrials.gov registry record · Phase 1
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase 1 study of Adenocarcinoma of the Rectum and Gastrointestinal Stromal Tumor, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT00397384: Completed Phase 1 study of Adenocarcinoma of the Rectum and Gastrointestinal Stromal Tumor, sponsored by National Cancer Institute (NCI).
NCT00397384 is a Phase 1 study of Adenocarcinoma of the Rectum and Gastrointestinal Stromal Tumor that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants, below the 908-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397384, a Phase 1 study of Adenocarcinoma of the Rectum and Gastrointestinal Stromal Tumor, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, or colorectal cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib hydrochloride and cetuximab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib hydrochloride together with cetuximab may kill more tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG cetuximab
- DRUG erlotinib hydrochloride
Study Locations (1)
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
What the finished NCT00397384 record still lists
NCT00397384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 908-participant average among 11 other Adenocarcinoma of the Rectum trials with a reported enrollment target (95% lower).
The record links to 10 conditions, with Adenocarcinoma of the Rectum appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00397384 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00397384 about?
NCT00397384 is a clinical study titled "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer". This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, or colorectal cancer. Erlotinib hydr...
What is the current status of trial NCT00397384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2007-01. Estimated completion is 2013-06.
What conditions does trial NCT00397384 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Rectum, Gastrointestinal Stromal Tumor, Adenocarcinoma of the Colon, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer.
What interventions are being tested in trial NCT00397384?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cetuximab (DRUG), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00397384?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00397384 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Rectum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00397384's enrollment target sits among peer trials
43 6th of 11 higher than 6 of 11 other Adenocarcinoma of the Rectum trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Rectum trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
COMPLETED · Phase 1
-
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
COMPLETED · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia